Broad Funding for Oxaliplatin in Ontario (Finally!)
Excerpt
Since the presentation of trials such as the Intergroup N9741 study (National Cancer Institute of Canada CO.15) and the MOSAIC (Multicenter International Study of Oxaliplatin/5-FU–LV in the Adjuvant Treatment of Colon Cancer) trial at the 2003 American Society of Clinical Oncology meeting, oncologists have broadly accepted that oxaliplatin is part of the standard management of colorectal cancer, both in the metastatic and adjuvant settings [...]
Share and Cite
Jonker, D.; Maroun, J.; Spithoff, K. Broad Funding for Oxaliplatin in Ontario (Finally!). Curr. Oncol. 2007, 14, 224-226. https://doi.org/10.3747/co.2007.155
Jonker D, Maroun J, Spithoff K. Broad Funding for Oxaliplatin in Ontario (Finally!). Current Oncology. 2007; 14(6):224-226. https://doi.org/10.3747/co.2007.155
Chicago/Turabian StyleJonker, Derek, J. Maroun, and K. Spithoff. 2007. "Broad Funding for Oxaliplatin in Ontario (Finally!)" Current Oncology 14, no. 6: 224-226. https://doi.org/10.3747/co.2007.155
APA StyleJonker, D., Maroun, J., & Spithoff, K. (2007). Broad Funding for Oxaliplatin in Ontario (Finally!). Current Oncology, 14(6), 224-226. https://doi.org/10.3747/co.2007.155